Boehringer Ingelheim Animal Health CEO Net Worth

Last Updated Mar 10, 2025
CEO NameJean Scheftsik de Szolnok
NationalityAustria
Net Worth Estimation$5 million

Jean Scheftsik de Szolnok, CEO of Boehringer Ingelheim Animal Health, is estimated to have a net worth of around $5 million based on executive compensation packages, performance bonuses, stock options, and his long tenure in senior management within the pharmaceutical industry. His net worth reflects both his annual salary and accumulated financial benefits from his roles at Boehringer Ingelheim and other leadership positions.

Jean Scheftsik de Szolnok's estimated net worth of $5,000,000 falls within the veterinary business CEO net worth range of $1,000,000 to $70,000,000. His net worth represents approximately 5.8% of the maximum estimated net worth for CEOs in this sector.

Business Category: Veterinary

Minimum Net Worth (estimation): 1000000 USD
Maximum Net Worth (estimation): 70000000 USD


Jean Scheftsik de Szolnok Performance in Boehringer Ingelheim Animal Health

Jean Scheftsik de Szolnok, CEO of Boehringer Ingelheim Animal Health, exemplifies strategic leadership through data-driven decision-making that accelerates innovation in animal health solutions. His performance is marked by strengthening global market presence and fostering sustainable growth via investment in research and technology. Under his leadership, the company has achieved enhanced operational efficiency and expanded its portfolio, significantly impacting industry standards and shareholder value.


Latest News

Boehringer Ingelheim Animal Health: Innovation and Leadership in Veterinary Medicine

Boehringer Ingelheim Animal Health focuses on innovative disease prevention and treatment for pets, horses, and livestock, supporting veterinarians, animal owners, and farmers. Recent leadership news includes Daniel Watkins appointed as leader of the US Pets business, while Brian Hilberdink leads US Human Pharma; the company emphasizes long-term R&D investment and growth, reporting strong 2025 performance with ongoing expansion in animal health[12].
Source: http://www.boehringer-ingelheim.com/animal-health



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Boehringer Ingelheim Animal Health are subject to change from time to time.

Comments

No comment yet